))
Episode 29 - Dr. Bhutani on the Efficacy and Safety of Tapinarof | The Future of Dermatology Podcast
Manage episode 411601115 series 3512836
Innehåll tillhandahållet av thefutureofdermatology. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av thefutureofdermatology eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Summary
In this episode, Dr. Farah Kamangar and Dr. Tina Bhutani discuss the efficacy and safety of Tapinarof, a non-steroidal topical therapy for psoriasis and atopic dermatitis. They highlight the impressive results of clinical trials, with 35-40% of psoriasis patients achieving clear or almost clear skin after 12 weeks of treatment. They also discuss the potential benefits of Tupinarof for atopic dermatitis patients. The side effects of folliculitis and headaches are mentioned, but overall, patients tolerate the medication well. The episode concludes with a discussion on the future of Tapinarof, including potential pediatric indications.
This episode is sponsored by an educational grant from the company Dermavant.
Takeaways
- Tapinarof is a non-steroidal topical therapy that has shown impressive efficacy in treating psoriasis, with 35-40% of patients achieving clear or almost clear skin after 12 weeks of treatment.
- The medication is also being studied for its effectiveness in treating atopic dermatitis, with early data showing promising results.
- Common side effects of Tapinarof include folliculitis and headaches, but overall, patients tolerate the medication well.
- The future of Tapinarof may include pediatric indications, which would be beneficial for parents looking for non-steroidal treatment options for their children.
- Gentle skincare techniques and moisturization may also play a role in managing psoriasis and improving skin barrier function.
35 episoder
Dela
